Stocks · News reference

Compass Pathways shares are trading higher after the company announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder.

Jul 16, 2026, 1:00 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 10:42 AMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $70 to $65.
Read original at benzinga
CMPS
BenzingaAug 6, 2026, 5:45 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18
Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $17 to $18.
Read original at benzinga
CMPS
BenzingaAug 6, 2026, 5:12 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21
RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and lowers the price target from $22 to $21.
Read original at benzinga
CMPS
BenzingaAug 6, 2026, 1:51 PMBenzinga Newsdesk
B. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22
B. Riley Securities analyst Madison El-Saadi maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $17 to $22.
Read original at benzinga
CMPS